Consideration of Muscle Mass in Glabellar Line Treatment With Botulinum Toxin Type A

September 2012 | Volume 11 | Issue 9 | Original Article | 1041 | Copyright © September 2012


Gary Monheit MD,a Xiaoming Lin MS RN,b Diane Nelson BSN MPH,b and Michael Kane MDc

aTotal Skin & Beauty Dermatology Center, Birmingham, AL;bMedicis Pharmaceutical Corporation, Scottsdale, AZ; cKane Plastic Surgery, New York, NY

DISCLOSURES

Gary Monheit MD has served as a consultant for: Allergan, Inc., Genzyme Corporation, Johnson & Johnson Pharmaceutical Research & Development, LLC., Ipsen, Medicis Pharmaceutical Corporation, Electro-Optical Sciences, Inc., Revance Therapeutics, Galderma Laboratories, LP, Mentor Corporation, and Merz Aesthetic Pharmaceuticals GmBH, and served as a clinical investigator for: Allergan, Inc., Dermik Laboratories, Genzyme Corporation, Contura International A/S, Ipsen, Medicis Pharmaceutical Corporation, Electro-Optical Sciences, Inc., Revance Therapeutics, Kythera Biopharmaceuticals, Galderma Laboratories, LP, Mentor Corporation, and Merz Pharmaceuticals. Xiaoming Lin is Vice President of Clinical Research and Development at Medicis Pharmaceutical Corporation, Scottsdale, AZ. Diane Nelson is Director of Medical Affairs at Medicis Pharmaceutical Corporation, Scottsdale, AZ. Michael Kane MD has served as a consultant for Merz Aesthetic Pharmaceuticals GmBH, Ulthera, Inc., Kythera Biopharmaceuticals, Inc., Lithera, Inc., Allergan, Inc., Bioform Medical, Inc., Canfield Scientific, Inc., Johnson & Johnson, Medicis Pharmaceutical Corporation, Q-Med, Revance Therapeutics, Inc., Shire, Sanofi-Aventis, and Stiefel Laboratories, Inc.; served as clinical investigator for: Medicis Pharmaceutical Corporation, Q-Med, and Sanofi-Aventis; and is a significant shareholder in: Allergan, Inc., and Medicis Pharmaceutical Corporation.

REFERENCES

  1. Carruthers A, Carruthers J. Cosmetic uses of botulinum A exotoxin. Adv Dermatol. 1997;12:325-347; discussion 348.
  2. Dysport® (abobotulinumtoxinA). Full Prescribing Information, Medicis Aesthetics Inc., Scottsdale, AZ, 2010.
  3. Xeomin® (incobotulinumtoxinA). Full Prescribing Information, Merz Pharmaceuticals, LLC, Greensboro, NC, 2011.
  4. BOTOX® Cosmetic (onabotulinumtoxinA). Full Prescribing Information, Allergan, Inc., Irvine, CA, 2010.
  5. Frevert J. Content of botulinum neurotoxin in Botox®/Vistabel®, Dysport ®/Azzalure®, and Xeomin®/Bocouture®. Drugs R D. 2010;10:67-73.
  6. Pickett A, Perrow K. Formulation composition of botulinum toxins in clinical use. J Drugs Dermatol. 2010;9:1085-1091.
  7. Brandt F, Swanson N, Baumann L, et al. Randomized, placebo-controlled study of a new botulinum toxin type A for treatment of glabellar lines: efficacy and safety. Dermatol Surg. 2009;35:1893-1901.
  8. Carruthers JA, Lowe NJ, Menter MA, et al. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol. 2002;46:840-849.
  9. Carruthers JD, Lowe NJ, Menter MA, et al. Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plast Reconstr Surg. 2003;112:1089-1098.
  10. Cohen JL, Schlessinger J, Cox SE, et al. An analysis of the long-term safety data of repeat administrations of botulinum neurotoxin type A-ABO for the treatment of glabellar lines. Aesthet Surg J. 2009;29:S43-S49.
  11. Fagien S, Cox SE, Finn JC, et al. Patient-reported outcomes with botulinum toxin type A treatment of glabellar rhytids: a double-blind, randomized, placebo-controlled study. Dermatol Surg. 2007;33:S2-9.
  12. Kane MA, Brandt F, Rohrich RJ, et al. Evaluation of variable-dose treatment with a new U.S. botulinum toxin type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase III, randomized, double-blind, placebo-controlled study. Plast Reconstr Surg. 2009;124:1619-1629.
  13. Monheit GD, Cohen JL. Long-term safety of repeated administrations of a new formulation of botulinum toxin type A in the treatment of glabellar lines: interim analysis from an open-label extension study. J Am Acad Dermatol. 2009;61:421-425.
  14. Moy R, Maas C, Monheit G, et al. Long-term safety and efficacy of a new botulinum toxin type A in treating glabellar lines. Arch Facial Plast Surg. 2009;11:77-83.
  15. Rubin MG, Dover J, Glogau RG, et al. The efficacy and safety of a new U.S. botulinum toxin type A in the retreatment of glabellar lines following open-label treatment. J Drugs Dermatol. 2009;8:439-444.
  16. Sattler G, Callander MJ, Grablowitz D, et al. Noninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown lines. Dermatol Surg. 2010;36:2146-2154.
  17. Kane M, Donofrio L, Ascher B, et al. Expanding the use of neurotoxins in facial aesthetics: a consensus panel's assessment and recommendations. J Drugs Dermatol. 2010;9:s7-22; quiz s23-25.
  18. Carruthers J, Fagien S, Matarasso SL. Consensus recommendations on the use of botulinum toxin type A in facial aesthetics. Plast Reconstr Surg. 2004;114:1S-22S.
  19. Carruthers A, Carruthers J, Said S. Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females. Dermatol Surg. 2005;31:414-422; discussion 422.
  20. Baumann L, Brandt FS, Kane MA, et al. An analysis of efficacy data from four phase III studies of botulinum neurotoxin type A-ABO for the treatment of glabellar lines Aesthet Surg J. 2009;29:S57-65.
  21. Carruthers A, Carruthers J. Botulinum toxin type A. J Am Acad Dermatol. 2005;53:284-290.
  22. Ascher B, Talarico S, Cassuto D, et al. International consensus recommendations on the aesthetic usage of botulinum toxin type A (Speywood Unit)--Part I: Upper facial wrinkles. J Eur Acad Dermatol Venereol. 2010;24:1278-1284.
  23. Benedetto AV, Lahti JG. Measurement of the anatomic position of the corrugator supercilii. Dermatol Surg. 2005;31:923-927.
  24. Janis JE, Ghavami A, Lemmon JA, et al. Anatomy of the corrugator supercilii muscle: part I. Corrugator topography Plast Reconstr Surg. 2007;120:1647-1653.
  25. Taylor S, Callender V, Lin X. Onset and durability of response of abobotulinumtoxinA for reduction of glabellar lines in patients with skin of color. Presented at: American Academy of Dermatology, February 4-8, 2011; New Orleans, LA.
  26. Grimes PE, Shabazz D. A four-month randomized, double-blind evaluation of the efficacy of botulinum toxin type A for the treatment of glabellar lines in women with skin types V and VI. Dermatol Surg. 2009;35:429-435; discussion 435-436.

ADDRESS FOR CORRESPONDENCE

Gary D. Monheit MD2100 16th Ave SSuite 202Birmingham, AL 35205-5067Phone: (205) 933-0987monheitgd421@pol.net
Close Menu